article thumbnail

Report: MA Enrollment Has Quadrupled in Rural Communities Since 2010

MedCity News

In rural areas, the share of eligible beneficiaries enrolled in MA plans nearly quadrupled from 11% in 2010 to 40% in 2023, according to new research from KFF. This represents 400,000 rural MA beneficiaries in 2010 and 1.8 million in 2023.

article thumbnail

NIH spending for drugs approved 2010-2019 lower than industry spending, study finds

European Pharmaceutical Review

billion for phased clinical trials of US Food and Drug Administration (FDA)-approved drugs between 2010-2019. million publications describing basic or applied research related to 386 of 387 drugs approved 2010-2019 with $8.1 This was ~10 percent of reported industry spending. billion (3.3

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

sBLA for New Formulation of Tesamorelin Issued Complete Response Letter by FDA

Pharmaceutical Commerce

Tesamorelin (Egrifta) was initially approved by the FDA in November 2010 for the treatment of lipodystrophy in patients also diagnosed with HIV.

FDA 52
article thumbnail

Eurofins BPT grows Cell & Gene Therapy US Footprint

PharmaTech

Eurofins BioPharma Product Testing (EBPT) in the US is a leading entity in the analytical testing of Cell and Gene Therapy, with its involvement dating back to 2010 at the Eurofins BPT Lancaster, PA location.

article thumbnail

Do patients care about accelerated approval drugs?

World of DTC Marketing

85% of accelerated approvals from 2010 to 2020 were for oncology indications. of approvals), cancer (35.6%), and other rare diseases (24.7%). Since then, accelerated Approval has shifted focus to oncology drugs.

Patients 200
article thumbnail

Moderna files lawsuits against Pfizer and BioNTech over mRNA technology

Pharmaceutical Technology

Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, is said to have infringed patents filed by Moderna between 2010 and 2016 for its mRNA technology. This technology was vital for developing Spikevax, an mRNA Covid-19 vaccine of Moderna.

article thumbnail

American health is in for a “world of hurt”

World of DTC Marketing

Cardiovascular disease deaths in the US have increased by nearly 17% since 2010, and are among the reasons that life expectancy in the U.S. has also seen reversals in health improvements since 2010, partly due to increasing rates of obesity, high blood pressure, and high blood sugar. . is lower than in other high-income countries.

Insurance 190